NASDAQ:SXTP
60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc.'s revenue grew 65.5% in fiscal 2025 to $1.0M while operating margin rose to −771.6%, its highest in 4 years. Free cash flow was −$7.0M, −695.1% of revenue, and the diluted share count rose 489.6%.Summary generated from 60 Degrees Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Mar 30, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$1.0M
Revenue growth+65.5%
Revenue, 5-yr CAGRn/a
Gross margin22.3%
Operating margin−771.6%
Net margin−732.5%
ROIC−264.8%
Return on equity−196.4%
Debt / equity0.04
Free cash flow−$7.0M
FCF margin−695.1%
Share count change+489.6%
Financials
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 1 | 1 |
| Operating income | −2 | −5 | −10 | −8 |
| Net income | −6 | −4 | −8 | −7 |
| Free cash flow | n/a | −5 | −6 | −7 |
Recent filings
- 8-KRegulation FD disclosure
Oct 6, 2026 - 8-KOther events
Sep 14, 2026 - 8-KRegulation FD disclosure
Sep 8, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KResults of a shareholder vote
Aug 6, 2026 - 8-KEntry into a material agreement
Aug 4, 2026 - 8-KRegulation FD disclosure
Jul 20, 2026 - 8-KOther events
Jul 9, 2026